Evaluating and treating the adult female patient with acne

Journal of Drugs in Dermatology

Volumn 12, Issue 12, 2013, Pages 1418-1427

  Zeichner, Joshua A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZELAIC ACID; BENZOYL PEROXIDE; DAPSONE; ISOTRETINOIN; ORAL CONTRACEPTIVE AGENT; RETINOID; SPIRONOLACTONE;

ACNE; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; FEMALE; HORMONAL THERAPY; HUMAN; PATHOGENESIS; TOPICAL TREATMENT; ACNE VULGARIS; ADOLESCENT; ADULT; AGE; DERMATOLOGY; ECONOMICS; MALE; METHODOLOGY; MIDDLE AGED; PREVALENCE; PSYCHOLOGICAL ASPECT; SEX DIFFERENCE; YOUNG ADULT;

ACNE VULGARIS; ADOLESCENT; ADULT; AGE FACTORS; DERMATOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SEX FACTORS; YOUNG ADULT;

EID: 84890911969     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (129)

1. James WD. Clinical practice: acne. N Engl J Med 2005; 352: 1463-72.
2. Thiboutot DM. Overview of acne and its treatment. Cutis. 2008;81(1 Suppl):3-7.
3. Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol 1971; 85 (2): 11-126.
4. Williams C, Layton AM. Persistent acne in women : implications for the patient and for therapy. Am J Clin Dermatol 2006; 7: 281-290.
5. Rivera R, Guerra A. Management of acne in women over 25 years of age.Actas Dermosifiliogr 2009; 100: 33-37.
6. Capitanio B, Sinagra JL, Bordignon V et al. Underestimated clinical features of postadolescent acne. J Am Acad Dermatol 2010; 63: 782-788.
7. Collier CN, Harper JC, Cantrell WC. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008;58:56-9.
8. Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J 1979 Apr 28;1(6171):1109-10.
9. Stern R. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol 1992;26:931-5.
10. Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001;15:541-5.
11. Goulden V, Clark S, Cunliffe W. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997;136:66-70.
12. Pawin H, Chivot M, Beylot, et al. Living with acne. A study of adolescents' personal experiences. Dermatology 2007;215(4):308-14.
13. McConnell RC, Fleischer AB Jr, Willford PM, Feldman SR. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: an analysis of the national ambulatory medical care survey, 1990-1994. J Am Acad Dermatol 1998;38:221-6.
14. Yentzer BA, Hick J, Reese EL, et al. Acne vulgaris in the United States: a descriptive epidemiology. Cutis. 2010 Aug; 86(2):94-9.
15. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-6
16. Baldwin HE. The interaction between acne vulgaris and the psyche. Cutis 2002 Aug;70(2):133-9.
17. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998 Nov; 139(5): 846-50.
18. Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch. 1971;242(1):12-29.
19. Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol. 2004 Jul;123(1):1-12. Review.
20. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun. 1995 Aug;63(8):3158-65.
21. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol. 1996 Jan;106(1):176-82. PubMed PMID: 8592071.
22. Guy R, Kealey T. Modelling the infundibulum in acne. Dermatology. 1998;196(1):32-7
23. Holmes RL, Williams M, Cunliffe WJ. Pilo-sebaceous duct obstruction and acne. Br J Dermatol. 1972 Oct;87(4):327-32.
24. Jeremy AHT, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121:20-27.
25. Burkhart CG, Burkhart CN. Expanding the microcomedone theory and acne therapeutics: Propionibacterium acnes biofilm produces biological glue that holds corneocytes together to form plug. J Am Acad Dermatol. 2007 Oct;57(4):722-4.
26. Ottaviani M, Camera E, Picardo M. Lipid mediators in acne. Mediators Inflamm. 2010;2010.
27. Leyden JJ, McGinley KJ, Mills OH, Kligman AM. Age-related changes in the resident bacterial flora of the human face. J Invest Dermatol. 1975 Oct;65(4):379-81.
28. Marples RR, Downing DT, Kligman AM. Control of free fatty acids in human surface lipids by Corynebacterium acnes. J Invest Dermatol. 1971 Feb;56(2):127-31.
29. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002 Aug 1;169(3):1535-41.
30. Kim J. Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology. 2005; 211(3): 193-8.
31. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004 Sep-Oct;22(5):419-28.
32. Kariya Y, Moriya T, Suzuki T, Chiba M, Ishida K, Takeyama J, Endoh M, Wata-nabe M, Sasano H. Sex steroid hormone receptors in human skin append-age and its neoplasms. Endocr J. 2005 Jun;52(3):317-25.
33. Thiboutot D, Gollnick H, Betolli V, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group. J Am Acad Dermatol. 2009; 60:S1-S50.
34. Held BL, Nader S, Rodriguez-Rigau LJ, Smith KD, Steinberger E. Acne and hyperandrogenism. J. Am. Acad. Dermatol.10(2 Pt 1), 223-226(1984).
35. Zoubolis C, Baron J, Bohm M, et al. Frontiers in sebaceous gland biology and pathology. Exp Dermatol. 2008;17:542-551.
36. Kariya Y, Moriya T, Suzuki T, Chiba M, Ishida K, Takeyama J, Endoh M, Wata-nabe M, Sasano H. Sex steroid hormone receptors in human skin append-age and its neoplasms. Endocr J. 2005 Jun;52(3):317-25.
37. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev. 2000 Aug;21(4):363-92.
38. Gilliver SC, Ashworth JJ, Ashcroft GS. The hormonal regulation of cutaneous wound healing. Clin Dermatol. 2007 Jan-Feb;25(1):56-62.
39. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995 Aug;105(2):209-14.
40. Kamangarl F and Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol 2012, 51, 1162-1174
41. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005 Jun18-24;365(9477):2125-36.
42. Lolis MS, Bowe WP, Shalita AR. Acne and systemic disease. Med Clin North Am. 2009 Nov;93(6):1161-81.
43. Maluki AH. The frequency of polycystic ovary syndrome in females with resistant acne vulgaris. J Cosmet Dermatol. 2010 Jun;9(2):142-8.
44. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005 Mar;141(3):333-8.
45. Tasli L, Turgut S, Kacar N, et al. Insulin-like growth factor-I gene polymorphism in acne vulgaris. J Eur Acad Dermatol Venereol. 2013 Feb;27(2):254-7.
46. Stubbs SA, Webber LJ, Stark J, et al. Role of Insulin-like Growth Factors in Initiation of Follicle Growth in Normal and Polycystic Human Ovaries. J Clin Endocrinol Metab. 2013 Aug;98(8):3298-305.
47. Yang MJ, Tseng JY, Chen CY, Yeh CC. Changes in maternal serum insulin- like growth factor-I during pregnancy and its relationship to maternal anthropometry. J Chin Med Assoc. 2013 Aug 12. pii: S1726-4901(13)00172-X. doi: 10.1016/j.jcma.2013.07.004. [Epub ahead of print]
48. Runchey SS, Pollak MN, Valsta LM, et al. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. Eur J Clin Nutr. 2012 Oct;66(10):1146-52.
49. Danby FW. Nutrition and acne. Clin Dermatol. 2010 Nov-Dec;28(6):598-604.
50. Smith RN, Braue A, Varigos GA et al. The effect of a low glycemic load diet on acne vulgaris and the fatty acid composition of skin surface triglycerides. J Dermatol Sci 2008; 50: 41-52.
51. Smith RN, Mann N, Makelainen H et al. A pilot study to determine the short- term effects of a low glycemic load diet on hormonal markers of acne: a nonrandomized, parallel controlled feeding trial. Mol Nutr Food Res 2008; 52: 718-726.
52. Smith RN, Mann NJ, Braue A et al. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J Am Acad Dermatol 2007; 57: 247-256.
53. Preneau S and Dreno B. Female acne - a different subtype of teenager acne? J Eur Acad Dermatol Venereol. 2012 Mar;26(3): 277-82.
54. Williams C, Layton AM. Persistent acne in women : implications for the patient and for therapy. Am J Clin Dermatol 2006; 7: 281-290.
55. Rivera R, Guerra A. Management of acne in women over 25 years of age. Actas Dermosifiliogr 2009; 100: 33-37.
56. Dreno B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol 2013, 27, 1063-1070
57. Dumont-Wallon G, Dreno B. Specificity of acne in women older than 25 years. Presse Med 2008; 37: 585-591.
58. Tan JKL, et al. Prevalence and severity of facial and truncal acne in a referral cohort. J Drugs Dermatol. 2008; 7 (6): 553-556.
59. Harper JC. Evaluating hyperandrogenism: a challenge in acne management. J Drugs Dermatol 2008; 7: 527-530.
60. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98: 89S-94S.
61. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA 2004; 292: 726-735.
62. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul;49(1Suppl):S1-37.
63. Villasenor J, Berson DS, and Kroshinsky D. Ch 8.2: Treatment guidelines in adult women. In Acne Vulgaris. Eds Shalita AR, Del Rosso JQ, and Webster GF. 1st edition. Informa Healthcare, London. 2011.
64. Ebede TL, et al. Hormonal Treatment of Acne in Women. J Clin Aesth Dermatol. 2009; 2 (12): 16-22.
65. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995; 98: 89S-94S.
66. Baldwin HE, Daniels, SR, Kawata AK, et al. Acne vulgaris in adult females: Healthcare resource utilization for treatment of facial acne. Poster Presented at the Fall Clinical Dermatology Conference. Las Vegas, NV. October 2012.
67. Landis ET, Levender MM, Davis SA, et al. Isotretinoin and oral contraceptive use in female acne patients varies by physician specialty: analysis of data from the National Ambulatory Medical Care Survey. J Dermatolog Treat. 2012 Aug;23(4):272-7
68. Thomas B, Tan JKL. Adherence optimization in acne management. Skin Ther Lett 2011; 7: 1-3.
69. Yentzer BA, Ade RA, Fountain JM, et al. Simplifying regimens promotes greater adherence and outcomes with topical acne medications: a randomized controlled trial. Cutis. 2010 Aug;86(2):103-8.
70. Berson D and Alexis A. Adapalene gel, 0.3% is efficacious in reducing acne lesions in adult women. Poster Presented at Summer Meeting of the American Academy of Dermatology. New York, NY. August, 2013.
71. Zeichner JA, Wong V, Linkner RV, and Haddican M. Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. J Drugs Dermatol. 2013 Mar;12(3):277-82.
72. Thielitz A, Abdel-Naser MB, Fluhr JW et al. Topical retinoids in acne- an evidence-based overview. J Dtsch Dermatol Ges 2008; 6: 1023-1031.
73. Schaefer H. Penetration and percutaneous absorption of topical retinoids. A review. Skin Pharmacol 1993; 6(Suppl 1): 17-23.
74. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993 May 22;341(8856):1352-3.
75. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993 May 8;341(8854):1181-2.
76. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D. et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998 Apr;32(4):505-6.
77. Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000 Jun;22(4):218-20.
78. Shapiro L, Pastuszak A, Curto G, Koren G. Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet. 1997 Oct 18;350(9085):1143-4.
79. Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005 Jul 15;136(2):117-21.
80. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: new perspectives on formulation and utilization. Dermatol Clin 2009; 27: 17-24.
81. Morelli R, Lanzarini M, Vincenzi C, et al. Contact dermatitis due to benzoyl peroxide. Contact Dermatitis 1989; 20 (3): 238-9
82. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opin. Pharmacother. 2009; 10(16):2555-2562.
83. Mills OH Jr, Kligman AM, Pochi P, Comite H. Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol. 1986;25:664-667.
84. Dosik JS, Vamvakias G. Comparative irritation potential of two combination acne products: a randomized controlled, subject- and evaluator-blind, comparative study in healthy volunteers. Am J Clin Dermatol. 2008;9:313-317.
85. Harper JC. Gender as a clinically relevant outcome variable in acne: benefits of a fixed combination clindamycin phosphate (1.2%) and benzoyl peroxide (2.5%) aqueous gel. J Drugs Dermatol 2012. 2012 Dec;11(12):1440-5.
86. Fernandez-Obregon A and Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003 Feb;71(2 Suppl):18-26.
87. Nacht S, Yeung D, Beasley JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol. 1981 Jan;4(1):31-7.
88. Morsches B and Holtzmann H. Studies on the percutaneous absorption of benzoyl peroxide (author's transl). Arzneimittelforschung. 1982; 32(3):298-300.
89. Saiz AI, et la. Determination of benzoyl peroxide and benzoic acid levels by HPLC during wheat flour bleaching process. J Agric Food Chem. 2001 Jan;49(1):98-102.
90. Rothman KF and Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol. 1988 Sep;19(3):431-42.
91. Toyoda M, Morohashi M. An overview of topical antibiotics for acne treatment. Dermatology 1998; 196: 130-134.
92. Guay DR. Topical clindamycin in the management of acne vulgaris. Expert Opin Pharmacother 2007; 8: 2625-2664.
93. Briggs GG, Freeman RK, Yaffe SJ: Drugs in pregnancy and lactation a reference guide to fetal and neonatal risk. 8th ed. Philadelphia, Pa.; London, Lippincott Williams & Wilkins, 2008. p. 384
94. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet. 2003 Mar 22;361(9362):983-8.
95. McCormack WM, Rosner B, Lee YH, et al. Effect on birth weight of erythromycin treatment of pregnant women. Obstet Gynecol. 1987 Feb;69(2):202-7.
96. Finacea Gel [package insert]. Morristown, NJ: Intendis, Inc; 2010
97. Azelex Cream [package insert]. Irvine, CA: Allergan; 2004
98. Del Rosso J, et al. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. J Drugs Dermatol. 2012 Jun;11(6): 694-700
99. Del Rosso JQ, Bhatia N. Azelaic acid gel 15% in the management of papulopustular rosacea: a status report on available efficacy data and clinical application. Cutis. 2011; 88: 67-72
100. Kircik L. Efficacy and Safety of azelaic acid (aza) Gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled Study. J Drugs Dermatol. 2011;10(6):586-590.
101. Akhavan, Bershad. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4(7):473-92.
102. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003 Oct 23;349(17):1628-35.
103. Zhu YI and Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001 Sep;45(3):420-34.
104. Tanghetti E, Harper JC, Oefelein MG. The efficacy and tolerability of dapsone 5% gel in female vs male patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol. 2012 Dec;11(12):1417-21.
105. Aczone Gel [package insert]. Irvine, CA: Allergan; 2013.
106. Dreno B, Bettoli V, Oschsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004 Nov-Dec;14(6):391-9.
107. Leyden JJ and Del Rosso JQ. Oral antibiotic therapy for acne vulgaris: pharmacokinetic and pharmacodynamic perspectives. J Clin Aesth Dermatol. 2011 Feb;4(2):40-7.
108. Thiboutot DM. Acne. An overview of clinical research findings. Dermatol Clin 1997; 15: 97-109.
109. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J Drugs Dermatol. 2010 Jun;9(6):655-64.
110. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol. 2002 May;146(5):840-8.
111. Leyden J, et al. Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris A Multicenter, Double-blind, Randomized, Parallel-Group Study. Arch Dermatol. 2006;142:605-612
112. Layton AM and Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol. 1992 Dec;27(6 Pt 2):S2-7.
113. Sardana K and Garg VK. Low-dose isotretinoin in acne vulgaris: a critical review. Dr J Dermatol. 2011 Sep;165(3):698-700.
114. Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010 Nov;51(4):248-53.
115. Preneau S, Dessinioti C, Nguyen JM, et al. Predictive markers of response to isotretinoin in female acne. Eur J Dermatol. 2013 Jun 24. [Epub ahead of print]
116. Schmitt JV, Tavares M, Cerci FB.Adult women with acne have a higher risk of elevated triglyceride levels with the use of oral isotretinoin. An Bras Dermatol. 2011 Jul-Aug;86(4):807-10.
117. Rodondi N, Darioli R, Ramelet AA, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy or acne: a pharmacogenetic study. Ann Intern Med. 2002 Apr 16;136(8):582-9.
118. Etminan M, Bird ST, Delaney JA, et al. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. JAMA Dermatol. 2013 Feb;149(2):216-20.
119. Thiboutot DM. Endocinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol. 2001; 15 (suppl 3): 57-61.
120. Thorneycroft IH. Evolution of progestins. Focus on the novel progestin drosperinone. J Reprod Med. 2002; 47 (11 Suppl):975-980.
121. Wallach M and Grimes DA. Modern Oral Contraception. Emron: Totowa, NJ. 2000.
122. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008 Apr;77(4):249-56.
123. Frangos JE, Alavian CN, Kimball AB. Acne and oral contraceptives: Update on women's health screening guidelines. J Am Acad Dermatol. May 2008; 58(5):781-786.
124. Kim GK and Del Rosso JQ. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris. J Clin Aesthet Dermatol. 2012 March; 5(3): 37-50.
125. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984;111: 209-14.
126. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003;206:57-67.
127. Shaw JC and White LE. Long-term safety of spironolactone in acne: results of an 8-year followup study. J Cutan Med Surg. 2002 Nov-Dec;6(6):541-5.
128. Aldactone [package insert]. New York, NY: Pfizer; 2012.
129. Briggs GG, Freeman RK, Yaffe S. In: Drugs in Pregnancy and Lactation, 7th ed. Briggs GG, Freeman RK, Yaffe S, editors. Philadelphia: Lippincott- Williams & Wilkins; pp. 1480-1481